BioNTech and its U.S. partner Pfizer have already begun manufacturing Covid-19 boosters that are adapted for multiple Omicron sub variants including BA.1, BA.4 and BA.5.
The FDA’s assessment comes just days before an independent panel is set to meet and decide whether to recommend approving the vaccine for young children.